World's First Chronic Migraine Therapy System Successfully Implanted in Six Patients

A new innovative device, designed to alleviate chronic migraine symptoms, has been implanted in six patients in Australia. Developed by ShiraTronics, this world's first implantable minimally invasive device signifies a major advancement in the treatment of migraines.

ShiraTronics, announced a landmark achievement with the successful implantation of its Chronic Migraine Therapy System (CMTS) in the world's first six patients, marking a significant breakthrough in migraine treatment. This innovative system, a major leap in clinical-stage medical devices, is the first fully implantable system for head location utilizing a minimally invasive approach. The RELIEV-CM study with leading neurologists highlights the system's potential to revolutionize chronic migraine therapy.

Engineered specifically to target and disrupt migraine signals within the head, the fully implantable system offers a promising alternative for patients seeking relief. Chronic migraine, the second leading cause of disability, affects approximately 2% of the global population, causing severe headaches, nausea, sensitivity to light, and reduced productivity. Unfortunately, many existing treatments offer little relief for these patients.

Lynn Elliott, Co-Founder of ShiraTronics expressed gratitude, remarking on the evolution of this innovative approach: 

"It is gratifying and humbling to witness the evolution of this innovative approach to treating chronic migraine. Originating as a visionary concept by a creative group of physicians, it has now materialized into a tangible reality that has the potential to restore quality of life to many enduring this debilitating condition."

Rob Binney, ShiraTronics' CEO, highlighted the successful completion of the trial, with all six patients opting for permanent implantation. This achievement underscores the effectiveness and promise of the ShiraTronics system, offering new hope to those afflicted.

The RELIEV-CM Study

The RELIEV-CM clinical study, conducted in partnership with leading Australian researchers, aims to evaluate the performance of the ShiraTronics Chronic Migraine System. The system works by delivering tailored electrical pulses to disrupt migraine pain signals, offering a more effective treatment alternative. Its fully programmable nature marks a significant improvement over previous therapies.

Dr Matthew Green, Director of Cercare, lauded the system's innovation, highlighting its simplicity: 

“I am thrilled to be at the forefront of medical innovation as the first to implant this groundbreaking neuromodulation product. The simplicity and swiftness of the minimally invasive procedure marks a substantial breakthrough procedurally, eliminating the complexities of previous therapies.”

This landmark achievement by ShiraTronics represents a significant advancement in treating chronic migraine sufferers. The successful implantation of the Chronic Migraine System not only validates the company's innovative approach but also shows promise in alleviating the burden faced by individuals suffering from this condition.

About Author: Tracy Mokwe

With over 3 years of experience as a medical laboratory scientist and writer, I am passionate about translating complex scientific information into clear and accessible content. My expertise lies in medical sciences, laboratory science and research, digital health, AI, and cybersecurity in healthcare.